Journal: iScience

Article Title: An oncolytic vaccinia virus encoding CD47 nanobody potentiates antitumor immunity in multiple myeloma

doi: 10.1016/j.isci.2026.115174

Figure Lengend Snippet: Enhanced antitumor efficacy of OVV-αCD47nb combined with proteasome inhibition in NS-1 tumors (A) Treatment scheme of OVV-αCD47nb and proteasome inhibitor combination therapy in NS-1 subcutaneous tumor model. Balb/c mice ( n = 4–5 per group) bearing subcutaneous NS-1 tumors (5×10 6 cells) received PBS, OVV-αCD47nb monotherapy (1 × 10 7 PFU/mouse), bortezomib monotherapy (1 mg/kg), or combination therapy for three times. (B) Schematic representation of tumor volume progression in mice. Once the tumor volume exceeded 2,000 mm3, the mouse was considered dead. (C) Tumor growth curves for each mouse. (D) Mouse survival curves. (E) Mouse body weight change curve. Data represent the mean ± standard deviation (SD) of ≥three independent experiments. Statistical significance was determined by two-way ANOVA with Tukey’s multiple-comparisons post-test. ns, not significant; ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001. S.C., subcutaneous; I.T., intratumoral; I.P., intraperitoneal.

Article Snippet: Bortezomib , MedChemExpress , Cat# HY-10227.

Techniques: Inhibition, Standard Deviation